TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Hansa Biopharma AB ( (SE:HNSA) ) is now available.
Hansa Biopharma announced a directed share issue of 17 million ordinary shares to facilitate their trading on Nasdaq Stockholm, with trading expected to commence around October 6, 2025. This move is part of Hansa’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its industry positioning and stakeholder interests.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company based in Lund, Sweden, focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation, with products like imlifidase and HNSA-5487.
Average Trading Volume: 534,308
Technical Sentiment Signal: Buy
Current Market Cap: SEK3.62B
Find detailed analytics on HNSA stock on TipRanks’ Stock Analysis page.